Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...

The guideline authors used data from 61 studies to provide recommendations on the use of neoadjuvant chemotherapy in patients with newly diagnosed, stage III-IV epithelial ovarian, fallopian tube, or ...

At the Research Awards 2024, we had the pleasure of hearing from Professor Anna DeFazio AM, University of Sydney, who heads ...

Global Ovarian Cancer Drugs Market size is expected to be worth around USD 9,857 Mn by 2032 from USD 3061 Mn in 2023, growing at a CAGR of 14.3% ...

While genetic testing rates for advanced ovarian cancer have increased, gaps in physician understanding and confidence in interpreting results may limit optimal biomarker-driven treatment and patient ...

Scroll down to know how chemotherapy, radiation, and surgery influence ovarian function, menopause, and hormonal balance.

Ovarian cancer is the deadliest gynecologic malignancy globally and is increasing in incidence and mortality with currently ...

Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new review suggests.

The BC Cancer Foundation is launching a fundraising campaign to support the next three years of immunotherapy research at BC ...

Nerve pain was most common in lung cancer patients, affecting more than 62%. This is probably because these patients ...

The U.S. Department of Health & Human Services may seek over $1 billion from Johnson & Johnson as reimbursement for federal ...